Drug Trial Radar · NCT05107115
Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine
Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
160
Actual
Start
Nov 24, 2021
Primary completion
Jul 19, 2023
Study completion Apr 23, 2024
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The first phase of this study will be a parallel, 12-week treatment, Phase 2, double-blind, 4 arm study to assess the safety and effectiveness of 3 oral doses of SAR444671 (rilzabrutinib), i.e. dose A, B and C, compared with placebo for decreasing the frequency and severity of itch and urticaria in male and female participants aged 18 years inclusive or older with CSU. After completion of the double-blind phase of the study, participants will be given the option of enrolling in the 40-week open label extension (OLE) phase of the study. Participants will receive open-label rilzabrutinib at dose B or dose C (the dose may be modified based on the 12-week safety and efficacy data). Due to the fact that some participants may be receiving rilzabrutinib for the first time, all participants will be monitored at Week 14, Week 16, Week 20, and Week 24. Afterwards, participants will be monitored at Week 36 and Week 52.
Conditions
- Chronic Spontaneous Urticaria
Interventions
rilzabrutinibDrug
Tablet, oral use
placeboDrug
Tablet, oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12Time frame: Baseline and Week 12
- Change From Baseline in Weekly Itch Severity Score (ISS7) at Week 12Time frame: Baseline and Week 12
Locations
128 sites in 13 countries. Site status is shown where the registry gives one.
Investigational Site Number : 0320001
Buenos Aires, Argentina
Investigational Site Number :0320001
Buenos Aires, Argentina
Investigational Site Number : 0320006
CABA, Buenos Aires, Argentina
Investigational Site Number :0320006
CABA, Buenos Aires, Argentina
Investigational Site Number : 0320002
CABA, Buenos Aires, Argentina
Investigational Site Number :0320002
CABA, Buenos Aires, Argentina
Investigational Site Number : 0320004
Rosario, Santa Fe Province, Argentina
Investigational Site Number : 0320005
Rosario, Santa Fe Province, Argentina
Investigational Site Number :0320004
Rosario, Santa Fe Province, Argentina
Investigational Site Number :0320005
Rosario, Santa Fe Province, Argentina
Investigational Site Number : 0320003
Rosario, Santa Fe Province, Argentina
Investigational Site Number :0320003
Rosario, Santa Fe Province, Argentina
Investigational Site Number : 1240003
Québec, Canada
Investigational Site Number :1240003
Québec, Canada
Investigational Site Number :1240010
Calgary, Alberta, Canada
Investigational Site Number : 1240009
Red Deer, Alberta, Canada
Investigational Site Number :1240009
Red Deer, Alberta, Canada
Investigational Site Number : 1240005
Toronto, Ontario, Canada
Investigational Site Number :1240005
Toronto, Ontario, Canada
Investigational Site Number : 1240004
Toronto, Ontario, Canada
Investigational Site Number :1240004
Toronto, Ontario, Canada
Investigational Site Number : 1240006
Montreal, Quebec, Canada
Investigational Site Number :1240006
Montreal, Quebec, Canada
Investigational Site Number : 1240002
Trois-Rivières, Quebec, Canada
Investigational Site Number :1240002
Trois-Rivières, Quebec, Canada
Investigational Site Number : 1520004
Osorno, Los Lagos Region, Chile
Investigational Site Number :1520004
Osorno, Los Lagos Region, Chile
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number :1520001
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number :1520003
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520002
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number :1520002
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number :2760002
Berlin, Germany
Investigational Site Number : 2760002
Berlin, Germany
Investigational Site Number : 2760001
Dresden, Germany
Investigational Site Number :2760001
Dresden, Germany
Investigational Site Number : 2760005
Kiel, Germany
Investigational Site Number :2760005
Kiel, Germany
Investigational Site Number : 2760004
Mainz, Germany
Investigational Site Number :2760004
Mainz, Germany
Showing 40 of 128 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.